|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
��ù�� |
|
���� |
| ��������������� | |
|
�� |
|
���� |
| PubMed | |
|
Article by CUI Fan |
|
Article by LIU Wei-da |
��Ϯ����ù�������ƽ�չ
��, ����
�й�ҽѧ��ѧԺ���й�Эҽ�ƴ�ѧƤ�����о���, �Ͼ� 210042
��ù��ͨ�����������������µĻ���.������Ϯ����ù��������ϵͳ�Ը�Ⱦ,��������.��ù�������ƾ�����ʮ��ķ�չ���˺ܴ��չ.�µĿ����ҩ����ߵ����Ʒ��Ͷ����������Ʒ����ij���,ʹ����Ϯ����ù�����ߵĴ����������������.���ڶ��ֿ����ҩ���ʹ���г��ֵ���ҩ����ҲӦ�������ע.
Progress in the Treatment of Invasive Aspergillosis
Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China
Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China
Aspergillosis usually occurs in immunocompromised population.Severe invasive aspergillosis can cause systemic infection,which may lead to death.After decades of development,obvious progress has been made in the treatment of aspergillosis.With the emergence of new antifungal agents,immunomodulation intervention and combination therapy,the survival rate of patients with invasive aspergillosis has been improved greatly. However,during the use of antifungal agents,more attention should be paid to the occurrence of drug resistance.
[2] Ostrosky-Zeichner L,Marr KA,Rex JH,et al.Amphotericin B:time for a new "gold standard".Clin Infect Dis,2003,37:415-425.
[3] Lin SJ,Schranz J,Teutsch SM.Aspergillosis case-fatality rate:systematic review of the literature.Clin Infect Dis,2001,32:358-366.
[4] Harbarth S,Pestotnik SL,Lloyd JF,et al.The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy.Am J Med,2001,111:528-534.
[5] Drew RH,Dodds Ashley E,Benjamin DK Jr,et al.Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients.Transplantation,2004,77:232-237.
[6] Alexander BD,Wingard JR.Study of renal safety in amphotericin B lipid complex-treated patients.Clin Infect Dis,2005,40(Suppl 6):S414-421.
[7] Chandrasekar PH,Ito JI.Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients.Clin Infect Dis,2005,40(Suppl 6):S392-400.
[8] Ito JI,Chandrasekar PH,Hooshmand-Rad R.Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA).Bone Marrow Transplant,2005,36:873-877.
[9] Denning DW,Ribaud P,Milpied N,et al.Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.Clin Infect Dis,2002,34:563-571.
[10] Herbrecht R,Denning DW,Patterson TF,et al.Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.N Engl J Med,2002,347:408-415.
[11] Lutsar I,Roffey S,Troke P.Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients.Clin Infect Dis,2003,37:728-732.
[12] Schwartz S,Thiel E.Update on the treatment of cerebral aspergillosis.Ann Hematol,2004,83 (Suppl 1):S42-44.
[13] Stone JA,Holland SD,Wickersham PJ,et al.Single-and multiple-dose pharmacokinetics of caspofungin in healthy men.Antimicrob Agents Chemother,2002,46:739-745.
[14] Walsh TJ,Teppler H,Donowitz GR,et al.Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.N Engl J Med,2004,351:1391-402.
[15] Kartsonis NA,Saah AJ,Joy Lipka C,et al.Salvage therapy with caspofungin for invasive aspergillosis:results from the caspofungin compassionate use study.J Infect,2005,50:196-205.
[16] Pancham S,Hemmaway C,New H,et al.Caspofungin for invasive fungal infections:combination treatment with liposomal amphotericin B in children undergoing hemopoietic stem cell transplantation.Pediatr Transplant,2005,9:254-257.
[17] Steinbach WJ,Stevens DA.Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis.Clin Infect Dis,2003,37(Suppl 3):S157-187.
[18] Nemunaitis J,Shannon-Dorcy K,Appelbaum FR,et al.Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor.Blood,1993,82:1422-1427.
[19] Denning DW,Marinus A,Cohen J,et al.An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients:diagnosis and therapeutic outcome.EORTC Invasive Fungal Infections Cooperative Group.J Infect,1998,37:173-180.
[20] Petraitis V,Petraitiene R,Sarafandi AA,et al.Combination therapy in treatment of experimental pulmonary aspergillosis:synergistic interaction between an antifungal triazole and an echinocandin.J Infect Dis,2003,187:1834-1843.
[21] Steinbach WJ,Stevens DA,Denning DW.Combination and sequential antifungal therapy for invasive aspergillosis:review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001.Clin Infect Dis,2003,37(Suppl 3):S188-224.
[22] Sionov E,Mendlovic S,Segal E.Experimental systemic murine aspergillosis:treatment with polyene and caspofungin combination and G-CSF.J Antimicrob Chemother,2005,56:594-597.
[23] Ehrmann S,Bastides F,Gissot V,et al.Cerebral aspergillosis in the critically ill:two cases of successful medical treatment.Intensive Care Med,2005,31:738-742.
[24] Dinser R,Grgic A,Kim YJ,et al.Successful treatment of disseminated aspergillosis with the combination of voriconazole,caspofungin,granulocyte transfusions,and surgery followed by allogeneic blood stem cell transplantation in a patient with primary failure of an autologous stem cell graft.Eur J Haematol,2005,74:438-441.
[25] Dannaoui E,Persat F,Monier MF,et al.In-vitro susceptibility of Aspergillus spp.isolates to amphotericin B and itraconazole.J Antimicrob Chemother,1999,44:553-555.
[26] Mosquera J,Denning DW.Azole cross-resistance in Aspergillus fumigatus.Antimicrob Agents Chemother,2002,46:556-557.
[27] Sutton DA,Sanche SE,Revankar SG,et al.In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus,with a head-to-head comparison to voriconazole.J Clin Microbiol,1999,37:2343-2345.
[28] Chandrasekar PH,Cutright JL,Manavathu EK.Aspergillus:rising frequency of clinical isolation and continued susceptibility to antifungal agents,1994-1999.Diagn Microbiol Infect Dis,2001,41:211-214.
[29] Kontoyiannis DP,Lewis RE,Sagar N,et al.Itraconazole-amphotericin B antagonism in Aspergillus fumigatus:an E-test-based strategy.Antimicrob Agents Chemother,2000,44:2915-2918.